|
|
|
|
| LEADER |
01000caa a22002652 4500 |
| 001 |
NLM111464722 |
| 003 |
DE-627 |
| 005 |
20250202124307.0 |
| 007 |
tu |
| 008 |
231222s2001 xx ||||| 00| ||jpn c |
| 028 |
5 |
2 |
|a pubmed25n0372.xml
|
| 035 |
|
|
|a (DE-627)NLM111464722
|
| 035 |
|
|
|a (NLM)11235215
|
| 040 |
|
|
|a DE-627
|b ger
|c DE-627
|e rakwb
|
| 041 |
|
|
|a jpn
|
| 100 |
1 |
|
|a Suzuki, Y
|e verfasserin
|4 aut
|
| 245 |
1 |
4 |
|a The efficacy and safety of terazosin and tamsulosin in patients with urinary disturbance accompanying prostatic hypertrophy
|
| 264 |
|
1 |
|c 2001
|
| 336 |
|
|
|a Text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a ohne Hilfsmittel zu benutzen
|b n
|2 rdamedia
|
| 338 |
|
|
|a Band
|b nc
|2 rdacarrier
|
| 500 |
|
|
|a Date Completed 17.05.2001
|
| 500 |
|
|
|a Date Revised 30.11.2018
|
| 500 |
|
|
|a published: Print
|
| 500 |
|
|
|a Citation Status MEDLINE
|
| 520 |
|
|
|a Terazosin (TE) and tamsulosin (TA) were allocated randomly to 38 patients who had urinary disturbance accompanying prostatic hypertrophy, and the efficacy and safety of the drugs were examined. Subjective symptoms due to I-PSS were improved significantly in both TE and TA groups. On the other hand, objective symptoms such as the maximum urinary flow and mean urinary flow were improved more in the TE group. TE showed hypotensive and cholesterol-decreasing effects in patients who also had hypertension and hyperlipemia. No unknown adverse reactions were observed in either groups, and the drugs were shown to be highly safe. TE was considered to be useful as the first choice drug for the patients with hypertension and or hyperlipemia and those with severe objective symptoms. TA was considered to be useful for the patients with impaired drug compliance or those with severe subjective symptoms though objective symptoms were not so severe
|
| 650 |
|
4 |
|a Clinical Trial
|
| 650 |
|
4 |
|a Journal Article
|
| 650 |
|
4 |
|a Randomized Controlled Trial
|
| 650 |
|
7 |
|a Adrenergic alpha-Antagonists
|2 NLM
|
| 650 |
|
7 |
|a Sulfonamides
|2 NLM
|
| 650 |
|
7 |
|a Terazosin
|2 NLM
|
| 650 |
|
7 |
|a 8L5014XET7
|2 NLM
|
| 650 |
|
7 |
|a Tamsulosin
|2 NLM
|
| 650 |
|
7 |
|a G3P28OML5I
|2 NLM
|
| 650 |
|
7 |
|a Prazosin
|2 NLM
|
| 650 |
|
7 |
|a XM03YJ541D
|2 NLM
|
| 700 |
1 |
|
|a Katoh, T
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Isurugi, K
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Obara, W
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Omori, S
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Goto, Y
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Fujioka, T
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Numasato, S
|e verfasserin
|4 aut
|
| 773 |
0 |
8 |
|i Enthalten in
|t Hinyokika kiyo. Acta urologica Japonica
|d 1962
|g 47(2001), 1 vom: 05. Jan., Seite 15-21
|w (DE-627)NLM012631779
|x 0018-1994
|7 nnns
|
| 773 |
1 |
8 |
|g volume:47
|g year:2001
|g number:1
|g day:05
|g month:01
|g pages:15-21
|
| 912 |
|
|
|a GBV_USEFLAG_A
|
| 912 |
|
|
|a SYSFLAG_A
|
| 912 |
|
|
|a GBV_NLM
|
| 912 |
|
|
|a GBV_ILN_20
|
| 912 |
|
|
|a GBV_ILN_22
|
| 912 |
|
|
|a GBV_ILN_40
|
| 912 |
|
|
|a GBV_ILN_60
|
| 912 |
|
|
|a GBV_ILN_72
|
| 912 |
|
|
|a GBV_ILN_120
|
| 912 |
|
|
|a GBV_ILN_350
|
| 912 |
|
|
|a GBV_ILN_2001
|
| 912 |
|
|
|a GBV_ILN_2003
|
| 912 |
|
|
|a GBV_ILN_2005
|
| 912 |
|
|
|a GBV_ILN_2006
|
| 912 |
|
|
|a GBV_ILN_2008
|
| 912 |
|
|
|a GBV_ILN_2010
|
| 912 |
|
|
|a GBV_ILN_2012
|
| 912 |
|
|
|a GBV_ILN_2018
|
| 951 |
|
|
|a AR
|
| 952 |
|
|
|d 47
|j 2001
|e 1
|b 05
|c 01
|h 15-21
|